Evofem Biosciences to Present at 20th Annual Global Investment Conference on September 6, 2018

SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today that the Company will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, as follows:


Thursday, September 6, 2018


11:40 a.m. EDT


Fontainebleau Foyer (2nd floor), St. Regis New York Hotel, New York City

(live and archive):

www.evofem.com in the "Investors" section under "Events and Presentations." 


Evofem's management team will also be available for one-on-one meetings with investors during the conference.  Institutional investors who would like to attend the presentation or schedule a one-on-one meeting with the Company may register for the conference at http://www.rodmanevents.com.

Evofem's lead product candidate, Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel, is being studied as a non-hormonal, on-demand vaginal contraceptive and for the prevention of certain sexually transmitted infections.

The Company expects to report top-line data by year-end 2018 from its confirmatory Phase 3 clinical trial of Amphora for contraception. Assuming positive results, Evofem expects to re-submit the Amphora New Drug Application (NDA) in the first half of 2019 which, if approved by the FDA, would position the Company to commercialize Amphora as the first and only hormone-free, on-demand contraceptive drug in early 2020.

A Phase 2b clinical trial of Amphora for the prevention of urogenital acquisition of Chlamydia trachomatis (primary endpoint) and Neisseria gonorrhea in women is also underway.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multi-purpose Prevention Technology vaginal gel to develop product candidates for multiple indications, including contraception, the prevention of urogenital transmission of chlamydia and gonorrhea in women, and recurrent bacterial vaginosis. For more information regarding Evofem, please visit www.evofem.com.

Forward-Looking Statements
Statements in this press release about Evofem's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company's control. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission (SEC), including its Quarterly Report for the period ended March 31, 2018, as filed with the SEC on Form 10-Q on May 14, 2018, and include but are not limited to the following: objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future; risks and uncertainties associated with market conditions; statements about the anticipated results of the Phase 3 clinical trial evaluating Amphora as a contraceptive and the Phase 2b clinical trial of Amphora to prevent urogenital acquisition of Chlamydia trachomatis and Neisseria gonorrhea in women, and any expected completion dates or general timing for these clinical trials; the Company's reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the Company's products; the impact of potential product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the Company's common stock, and the concentration of power in its stock ownership. Forward-looking statements in this press release are made as of the date of this press release, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Evofem's views as of any date subsequent to the date hereof.

Investor Contact
Amy Raskopf
Evofem Biosciences, Inc.
O: 858-550-1900 x167

Media Contact
Sophia Ononye
O: (646) 599-8630
M: (917) 557-1909


SOURCE Evofem Biosciences, Inc.